TGF-β signaling shows promise in short-term animal models, but its effects in human liver disease are more complex, requiring precise intervention in the right cell type at the appropriate disease stage to achieve therapeutic benefit (Meindl-Beinker et al., 2012) (Tables 1–3). Here, TGFB1 is linked to liver disorder.